SOUTH SAN FRANCISCO, Calif., June 29, 2017 /PRNewswire/
-- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP)
announced today that the company and its ProNeura™ long-term, continuous drug delivery technology have been featured in
Fortune in an article titled "The Buzzy New Technology That Could
Make Pills Obsolete."
The article discusses how "pharmaceutical implants, matchstick-size devices that deliver drugs to patients over a period of
weeks or months, are coming into their own." Specifically, the article highlights Titan's FDA-approved Probuphine®
(buprenorphine) implant product, which treats opioid addiction by providing continuous doses of buprenorphine for up to six
months, and that is being commercialized in the United States by its partner, Braeburn
Pharmaceuticals, as well as Titan's development of its ProNeura implantable technology for Parkinson's disease.
In addition to the article, Fortune posted an in-depth video interview with Dr. Kate
Beebe, Titan's executive vice president and chief development officer. The article and video appear online here and a version
of the article is expected to appear in the July 1 print issue of Fortune.
About Titan Pharmaceuticals
Titan Pharmaceuticals Inc. (NASDAQ: TTNP), based in South San Francisco, CA, is
developing proprietary therapeutics primarily for the treatment of serious medical disorders. The company's lead product is
Probuphine®, a novel and long-acting formulation of buprenorphine for the long-term maintenance treatment of opioid dependence.
Probuphine employs Titan's proprietary drug delivery system ProNeura™, which is capable of delivering sustained, consistent
levels of medication for three months or longer. Titan has granted commercial rights in the U.S. and Canada for Probuphine to Braeburn Pharmaceuticals. Approved by the U.S. Food and Drug Administration in
May 2016, Probuphine is the first and only commercialized treatment of opioid dependence to provide
continuous, around-the-clock blood levels of buprenorphine for six months following a single procedure. The ProNeura technology
has the potential to be used in developing products for treating other chronic conditions such as Parkinson's disease and
hypothyroidism, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve
medical outcomes. For more information about Titan, please visit www.titanpharm.com.
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933
and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating
to our product development programs and any other statements that are not historical facts. Such statements involve risks and
uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that
could cause actual results to differ materially from management's current expectations include those risks and uncertainties
relating to the commercialization of Probuphine, the regulatory approval process, the development, testing, production and
marketing of our drug candidates, patent and intellectual property matters and strategic agreements and relationships. We
expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any
such statement is based, except as required by law.
CONTACT:
Titan Pharmaceuticals, Inc.:
Sunil Bhonsle, President
(650) 244-4990
Investors:
Stephen Kilmer
(650) 989-2215
skilmer@titanpharm.com
Media:
Susan Thomas
(650) 989-2216
sthomas@titanpharm.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/fortune-article-highlights-titan-pharmaceuticals-and-its-proneura-technology-300481702.html
SOURCE Titan Pharmaceuticals, Inc.